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Objectives:  Guidelines  for the conduct  of  clinical  trials emphasize  the  importance  of keeping  the  interim
results  from  the  main  endpoints  conﬁdential,  in  order  to  maintain  the  integrity  of  the  trial  and  to  safeguard
patients’  interests.  However,  is this  essential  in  every  situation?
Materials  and methods:  We  review  the  evidence  for these  guidelines  and  consider  recent  randomised  trials
that have released  interim  results,  to assess  their  impact  on the  success  of  the  trial.  However,  because  the
strength of  opinion  to keep  interim  results  conﬁdential  is  so  strong,  there  are  limited  examples  of such
trials.
Results:  In the QUARTZ  trial (which  is assessing  the  value  of  whole  brain  radiotherapy  in  patients  with
brain  metastases  from  non-small  cell lung  cancer)  the  decision  to release  interim  results  was  taken  in
response  to  threatened  closure  due  to poor  accrual,  whereas  in the  GRIT  trial  (which  compared  two
obstetric  strategies  for  the  delivery  of  growth  retarded  pre-term  fetuses)  the  regular  release  of  interim
results  was pre-planned.  Nevertheless  there  are  a number  of  common  factors  between  these  two  trials.  In
particular,  the  trial  treatments  were  already  in  wide  use,  with  no reliable  randomised  evidence  on  which
treatment  should  be  used  for  which  patients,  and  there  was  diverse  clinical  opinion,  which  meant  that
accrual  was  likely  to be challenging.  In  a situation  where  a quarter  to a  third  of trials  do  not  accrue  their
required  number  of patients,  the QUARTZ  trial  continues  to accrue  patients,  and  the GRIT trial  successfully
accrued  its target  of  nearly  600  babies.
Conclusions:  This  article  therefore  argues  that  there  is  a need  to  re-consider  whether  it is always  essential
to  keep  the  interim  results  of  randomized  clinical  trials  conﬁdential,  and  suggests  some  criteria  that  may
help groups  planning  or running  challenging  trials decide  whether  releasing  interim  results  would  be a
useful  strategy.
©  2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC. Introduction
In the early days of randomised clinical trials, the common
ractice was to keep investigators informed about the results as
hey accumulated during the course of the trial. However, during
he 1980s, maintaining the conﬁdentiality of interim results gradu-
lly became accepted as a cornerstone of good clinical trial practice,
stensibly to avoid the risk of widespread pre-judgment of unre-
iable results based on limited data, and thus safeguard patient
nterests and enhance trial integrity and credibility.
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However, the evidence for this seems scanty. For example, Ellen-
berg et al. [1] mainly base their recommendations on two studies.
Firstly, a retrospective analysis of evolving outcomes in a trial of
2 anti-retroviral agents for HIV infected patients [2]. At the ﬁrst
Data Monitoring Committee (DMC) meeting there had been 19 pro-
gressions or deaths on the didanosine arm vs 39 on the zalcitabine
arm (p = 0.009), but as the difference had not reached the protocol-
speciﬁed stopping rule, the DMC  allowed the trial to continue. By
the ﬁnal DMC  meeting this difference had disappeared (157 vs 152
events) [3]. The assumption was that if the early interim results
had been made public the trial would have stopped. The second
piece of evidence was a matched-analysis of the 10 most recent
randomized trials run by 2 major US Cancer Cooperative Groups
[4]. The analysis indicated that in the Group that released interim
results to investigators, accrual declined in half of the trials, and
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ne trial was inappropriately terminated early. Whereas the trials
un by the Group that kept interim results conﬁdential were con-
idered free of problems. However, as the authors admit: ‘there are
any differences between the Groups that could have contributed
o this’.
Despite this apparent lack of evidence, numerous papers [5,6]
eiterate this widely held view that releasing interim results
estroys the integrity of a trial and operates against the interests of
atients. Subsequent challenges to this new orthodoxy have been
are. Thus when an editorial [7] argued for the release of interim
ata in certain circumstances, and that it was unethical to withhold
nterim results from patients already on, or considering joining,
 trial, it provoked numerous responses, citing the risk of unpre-
ictable point estimates, pressures from interested parties, and
he importance of relying on the DMC  for independent decision-
aking.
Nevertheless, we argue that there are speciﬁc circumstances
here releasing interim results will enable challenging trials to be
ompleted successfully, and will not destroy the trial’s integrity
r credibility. We  describe two instances where this alternative
pproach has been taken.
. Recent trials that have released interim results
The QUARTZ trial was launched in December 2006 with the aim
f accruing 1000 patients to investigate the value of whole brain
adiotherapy (WBRT) for patients with inoperable brain metas-
ases from non-small cell lung cancer (NSCLC). For decades, WBRT
as been advocated for such patients, but it can cause signiﬁ-
ant toxicity, and overall beneﬁts have never been demonstrated
n a randomised clinical trial. As a result different clinicians use
ifferent criteria to select which patients should, or should not,
eceive WBRT. However, by March 2010 only 144 patients had been
ecruited, and the future of the trial was in doubt.
Numerous attempts had been made to increase accrual, includ-
ng presentations at national meetings, teleconferences with
nvestigators to discuss recruitment strategies, newsletters, visits
o centres, editorials in journals, and reducing the sample size to
34 patients (based on the event rate in the ﬁrst 50 patients in the
ontrol group), but accrual rarely reached the required target of at
east 10 patients a month.
Therefore it was proposed that the interim results should be
eleased. The rationale behind this was the belief that a key reason
or the poor accrual was the lack of any preliminary randomised
ata to support the trial’s hypothesis that omitting WBRT was
nlikely to be detrimental in terms of either survival or quality of
ife. The proposal was discussed with the trial’s oversight commit-
ees and funders, neither of whom had knowledge of the interim
esults (as this might have biased their judgment), and approval for
he release was granted following extensive discussions regarding
he options and implications. The interim results were presented
o investigators on 1st October 2010, with input from senior statis-
icians to avoid over-interpretation. The interim results (which
howed no clear evidence of a difference between the trial groups),
ere subsequently published [8].
In the 12 months prior to the release of these interim results,
ccrual averaged 6.92 patients a month, and in the subsequent
2 months this increased slightly to 8.75 patients, although this
ay  simply reﬂect the underlying increase in accrual seen over
ime and/or the added publicity about the trial, but importantly
he trial was able to continue. By the end of December 2012, 398
atients had been randomized, and trial is now on course to com-
lete accrual.
The Growth Restriction Intervention Trial (GRIT) compared two
bstetric strategies for the delivery of growth retarded pre-termcer 85 (2014) 116–118 117
fetuses: relatively early delivery (to pre-empt terminal hypox-
aemia) compared with delaying delivery for as long as possible
(to increase fetal maturity). Preliminary structured analyses had
revealed that obstetricians were using both of these approaches,
and were using different criteria to decide which approach to adopt,
and thus did not have sufﬁcient uncertainty about which individ-
ual patients would be eligible for a randomized comparison. It
was decided to release the interim results to the participants at
each investigator meeting in the hope that this might re-assure
individual obstetricians about the approach they did not usually
favour, and thus increase their willingness to approach women
about the trial [9,10]. The trial design avoided frequentist statis-
tical concerns regarding multiple interim analysis by adoption of
a Bayesian updating approach [11]. GRIT successfully accrued 588
babies, and provided important evidence to inform practice [12,13]
and thus the fact that interim results had been regularly released
to all participants does not seem to have affected the integrity
of the trial. Indeed it can be argued that a trial which releases
interim results and continues to complete target accrual is likely
to be far more credible than a trial which terminates early for poor
accrual.
3. Criteria for the release of interim results
The experience of the QUARTZ and GRIT trials has been that
the release of interim results has not compromised the success of
the trial, but actually helped the trials to continue. Although these
two trials are very different, they nevertheless have a number of
factors in common, which might form the criteria that other groups
running challenging trials might consider when assessing whether
to release interim results:
• All trial treatments were already in wide use, with no reliable ran-
domised evidence on which treatment should be used for which
patients.
• There was  diverse and strongly held clinical opinion, which
meant that accrual was likely to be challenging.
• The trials employed short-term interventions, meaning that dis-
closure of the interim results would not impact on the treatment
of current patients, and trial comparisons.
• A sufﬁcient number of reliable outcomes were available in order
to make comparisons.
Thus we  believe that, when all other attempts to revive declining
accrual has failed, trial groups should consider the possibility of
releasing interim results, although the operating characteristics of
each trial need to be considered carefully from both scientiﬁc and
ethical perspectives.
Any consideration of releasing interim results will be a judg-
ment call, and must weigh up the risks that releasing interim results
may  be over-interpreted, may  negatively affect accrual, and/or may
affect subsequent secondary treatment (and thus bias long-term
results), against the risk of the trial failing to accrue sufﬁcient
patients to produce a reliable result. The interim results from the
two trials described above were non-signiﬁcant and of course raise
the issue of whether an interim, potentially false-positive, result
would have caused the trials to stop inappropriately prematurely.
Unfortunately given the lack of trials where interim results have
been released we can only speculate how participants might react
to seeing a signiﬁcant result, but, as indicated above, it is vital that
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. Conclusions
It is always important to revisit and reﬂect on current practice.
e increasingly live in a climate of freedom of information, trans-
arency and openness, the research and clinical communities are
ow more knowledgeable about trials, the proﬁle of clinical trials is
igher, the Internet allows everyone greater access to information,
nd the concepts of uncertainty and risk are more widely discussed.
vidence-based medicine depends on sufﬁciently large amounts
f evidence from randomized trials. Therefore any trial group that
ails to predict poor accrual and/or stops the trial prematurely due
o failure to accrue (it has been estimated that between a quarter
nd a third of trials do not achieve their planned accrual [14,15])
ails to advance knowledge and squanders resources as well as the
oodwill of participating patients, which represents an unaccept-
ble waste of research funding, investigators time, and patients
oodwill. In these circumstances, we believe there is a need to
econsider and debate the current attitudes towards the release
f interim data.
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